EPHA1 and glioblastoma: PPI-inhibitors (PPI-is) targeting Eph/ephrin systems [19–21] have been already described: UniPR1331 is an orally bioavailable pan-Eph PPI-i with potential for the treatment of glioblastoma [14, 22] that is also able to inhibit VEGF-induced neovascularization in vivo [14].